Tudor Investment Corp ET AL Lowers Holdings in Bioventus Inc. (NYSE:BVS)

Tudor Investment Corp ET AL reduced its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 17.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 211,304 shares of the company's stock after selling 45,830 shares during the period. Tudor Investment Corp ET AL owned about 0.26% of Bioventus worth $2,219,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in BVS. Tower Research Capital LLC TRC increased its position in shares of Bioventus by 106.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock worth $36,000 after acquiring an additional 1,786 shares during the period. Plato Investment Management Ltd purchased a new stake in Bioventus during the 4th quarter worth about $38,000. KLP Kapitalforvaltning AS acquired a new stake in Bioventus in the 4th quarter valued at about $75,000. Quantbot Technologies LP purchased a new position in shares of Bioventus in the 4th quarter valued at about $103,000. Finally, Arizona State Retirement System acquired a new position in shares of Bioventus during the fourth quarter worth about $109,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Stock Up 1.1 %

Bioventus stock opened at $7.34 on Friday. Bioventus Inc. has a 1-year low of $3.95 and a 1-year high of $14.38. The stock has a market cap of $601.47 million, a PE ratio of -12.03 and a beta of 0.92. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock's fifty day moving average is $8.74 and its two-hundred day moving average is $10.29.

Insider Buying and Selling

In other news, SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares in the company, valued at approximately $1,204,233.82. The trade was a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Leonard Singleton sold 3,875 shares of the company's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the completion of the sale, the chief financial officer now directly owns 141,088 shares of the company's stock, valued at approximately $1,068,036.16. This trade represents a 2.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,208 shares of company stock worth $226,138 over the last 90 days. 32.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, March 17th.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.

Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NYSE:BVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.